145 related articles for article (PubMed ID: 32825958)
1. HER2 genomic heterogeneity is a frequent event in gastroesophageal adenocarcinoma and correlates with tumor morphology.
Machado-Neves R; Vale J; Eloy C; Polónia A
Pathol Res Pract; 2020 Sep; 216(9):153090. PubMed ID: 32825958
[TBL] [Abstract][Full Text] [Related]
2. Comparing the 2017 ASCO/CAP guideline for gastroesophageal adenocarcinoma surgical specimen to the 2018 ASCO/CAP guideline for breast cancer in assessing the HER2 status in primary mucinous ovarian carcinoma.
Chao WR; Lee MY; Lee YJ; Sheu GT; Han CP
Virchows Arch; 2022 May; 480(5):1023-1030. PubMed ID: 35226147
[TBL] [Abstract][Full Text] [Related]
3. Gene status in HER2 equivocal breast carcinomas: impact of distinct recommendations and contribution of a polymerase chain reaction-based method.
Sapino A; Maletta F; Verdun di Cantogno L; Macrì L; Botta C; Gugliotta P; Scalzo MS; Annaratone L; Balmativola D; Pietribiasi F; Bernardi P; Arisio R; Viberti L; Guzzetti S; Orlassino R; Ercolani C; Mottolese M; Viale G; Marchiò C
Oncologist; 2014 Nov; 19(11):1118-26. PubMed ID: 25323485
[TBL] [Abstract][Full Text] [Related]
4. Breast carcinomas with low amplified/equivocal HER2 by Ish: potential supporting role of multiplex ligation-dependent probe amplification.
Ercolani C; Marchiò C; Di Benedetto A; Fabi A; Perracchio L; Vici P; Sperati F; Buglioni S; Arena V; Pescarmona E; Sapino A; Terrenato I; Mottolese M
J Exp Clin Cancer Res; 2017 Oct; 36(1):143. PubMed ID: 29029640
[TBL] [Abstract][Full Text] [Related]
5. The updated 2018 American Society of Clinical Oncology/College of American Pathologists guideline on human epidermal growth factor receptor 2 interpretation in breast cancer: comparison with previous guidelines and clinical significance of the proposed in situ hybridization groups.
Woo JW; Lee K; Chung YR; Jang MH; Ahn S; Park SY
Hum Pathol; 2020 Apr; 98():10-21. PubMed ID: 32027910
[TBL] [Abstract][Full Text] [Related]
6. What to expect from the 2018 ASCO/CAP HER2 guideline in the reflex in situ hybridization test of immunohistochemically equivocal 2+ cases?
Curado M; Caramelo AS; Eloy C; Polónia A
Virchows Arch; 2019 Sep; 475(3):303-311. PubMed ID: 30953146
[TBL] [Abstract][Full Text] [Related]
7. HER2 in situ hybridization in gastric and gastroesophageal adenocarcinoma: comparison of automated dual ISH to FISH.
Grin A; Brezden-Masley C; Bauer S; Streutker CJ
Appl Immunohistochem Mol Morphol; 2013 Dec; 21(6):561-6. PubMed ID: 23455182
[TBL] [Abstract][Full Text] [Related]
8.
Klempner SJ; Madison R; Pujara V; Ross JS; Miller VA; Ali SM; Schrock AB; Kim ST; Maron SB; Dayyani F; Catenacci DVT; Lee J; Chao J
Oncologist; 2019 Nov; 24(11):1462-1468. PubMed ID: 31249137
[TBL] [Abstract][Full Text] [Related]
9. Equivocal (HER2 IHC 2+) breast carcinomas: gene-protein assay testing reveals association between genetic heterogeneity, individual cell amplification status and potential treatment benefits.
Pekar G; Kasselaki I; Pekar-Lukacs A; Dekany C; Hellberg D; Tot T
Histopathology; 2019 Jan; 74(2):300-310. PubMed ID: 30113715
[TBL] [Abstract][Full Text] [Related]
10. [Amplification of HER2 gene in gastric carcinoma detected by dual in-situ hybridization].
Sin LF; Vong HT; Wen JM; Yip YC
Zhonghua Bing Li Xue Za Zhi; 2012 Mar; 41(3):168-71. PubMed ID: 22800479
[TBL] [Abstract][Full Text] [Related]
11. HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment.
Kunz PL; Mojtahed A; Fisher GA; Ford JM; Chang DT; Balise RR; Bangs CD; Cherry AM; Pai RK
Appl Immunohistochem Mol Morphol; 2012 Jan; 20(1):13-24. PubMed ID: 21617522
[TBL] [Abstract][Full Text] [Related]
12. The spectrum of HER2 expression in breast cancer: linking immunohistochemistry quantification with in situ hybridization assay.
Polónia A; Canelas C; Caramelo A
Virchows Arch; 2022 Jun; 480(6):1171-1179. PubMed ID: 35137279
[TBL] [Abstract][Full Text] [Related]
13. New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers.
Tchrakian N; Flanagan L; Harford J; Gannon JM; Quinn CM
Virchows Arch; 2016 Feb; 468(2):207-11. PubMed ID: 26521061
[TBL] [Abstract][Full Text] [Related]
14. Analysis of molecular subtypes for the increased HER2 equivocal cases caused by application of the updated 2013 ASCO/CAP HER2 testing guidelines in breast cancer.
Guo L; Yuan P; Zhang J; Ling Y; Li W; Zhao B; Ying J; Xuan L
Breast Cancer Res Treat; 2017 Nov; 166(1):77-84. PubMed ID: 28712009
[TBL] [Abstract][Full Text] [Related]
15. Characterization of HER2 gene amplification heterogeneity in invasive and in situ breast cancer using bright-field in situ hybridization.
Polónia A; Oliveira G; Schmitt F
Virchows Arch; 2017 Nov; 471(5):589-598. PubMed ID: 28702778
[TBL] [Abstract][Full Text] [Related]
16. HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population.
Shan L; Ying J; Lu N
Diagn Pathol; 2013 May; 8():76. PubMed ID: 23656792
[TBL] [Abstract][Full Text] [Related]
17. Application of the 2013 ASCO/CAP guideline and the SISH technique for HER2 testing of breast cancer selects more patients for anti-HER2 treatment.
Polónia A; Leitão D; Schmitt F
Virchows Arch; 2016 Apr; 468(4):417-23. PubMed ID: 26754674
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Expression of Human Epidermal Growth Factor Receptor 2 (HER2) in Gastric and Gastroesophageal Junction Adenocarcinoma Using IHC and Dual-ISH.
Dominguez C; Rosa M; George TB; Pimiento J; Lauwers GY; Coppola D
Anticancer Res; 2018 Jan; 38(1):367-372. PubMed ID: 29277796
[TBL] [Abstract][Full Text] [Related]
19. HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma.
Plum PS; Gebauer F; Krämer M; Alakus H; Berlth F; Chon SH; Schiffmann L; Zander T; Büttner R; Hölscher AH; Bruns CJ; Quaas A; Loeser H
BMC Cancer; 2019 Jan; 19(1):38. PubMed ID: 30621632
[TBL] [Abstract][Full Text] [Related]
20. HER2 immunohistochemistry significantly overestimates HER2 amplification in uterine papillary serous carcinomas.
Mentrikoski MJ; Stoler MH
Am J Surg Pathol; 2014 Jun; 38(6):844-51. PubMed ID: 24698965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]